Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06633835 · ClinicalTrials.gov registry record · Phase 4
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
A Phase 4 study of COVID-19 and SARS CoV 2 Infection, sponsored by Novavax.
- Active
- Registry status
- Phase 4
- Development phase
- 660
- Enrollment target
- 1
- Study location
NCT06633835: Active Phase 4 study of COVID-19 and SARS CoV 2 Infection, sponsored by Novavax.
NCT06633835 is a Phase 4 study of COVID-19 and SARS CoV 2 Infection that is active but no longer recruiting, run by Novavax. The registered enrollment target is 660 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06633835, a Phase 4 study of COVID-19 and SARS CoV 2 Infection, is active but no longer recruiting, sponsored by Novavax.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 660 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
Primary Outcome
Percentage of participants that experienced any solicited systemic reactogenicity symptoms after receiving a single dose of 2024-25 Novavax COVID-19 vaccine or 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine during the first two days post vaccination.
Conditions Studied
Interventions
- BIOLOGICAL protein subunit: Novavax COVID-19 vaccine
- BIOLOGICAL Pfizer mRNA COVID-19 vaccine
Study Locations (1)
Utah
- University of Utah School of Medicine - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 4 |
What the registry record for NCT06633835 still lists
NCT06633835 is an interventional study that assigns participants to a tested intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which protein subunit: Novavax COVID-19 vaccine is the first listed.
NCT06633835 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06633835 about?
NCT06633835 is a clinical study titled "Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States". To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
What is the current status of trial NCT06633835?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 660 participants. The study started on 2024-09-20. Estimated completion is 2025-08-31.
What conditions does trial NCT06633835 study?
This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection, Vaccine-Preventable Diseases.
What interventions are being tested in trial NCT06633835?
The interventions under investigation include: protein subunit: Novavax COVID-19 vaccine (BIOLOGICAL), Pfizer mRNA COVID-19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06633835?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06633835 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06633835's enrollment target sits among peer trials
660 96th of 298 higher than 202 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- NCT05470205 · 660 participants · Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI